Scope Covered by Indicator Sample Clauses

Scope Covered by Indicator. Aircraft parking stands, in contact with the terminal and off terminal, which can be used for commercial treatment, excluding private spaces; - The platforms concerned are those of Paris-CDG and Paris-Orly.
Sample 1
AutoNDA by SimpleDocs
Scope Covered by Indicator. Airbridges; - The platforms concerned are those of Paris-CDG and Paris-Orly.
Sample 1
Scope Covered by Indicator. The various types of electro-mechanical equipment are as follows: - lifts available for the public, including platforms for mobility impaired persons, - other lifts used to carry a passenger or his luggage, - moving walkways, - escalators. - The equipment covered is that which is located in passenger terminals; - for reasons of homogeneous treatment, the equipment of the Roissypole SNCF station, the lifts of the Module d'Echanges and the lifts and escalators of the Orlyval stations in Orly-Sud are not taken into account in the perimeter; - The platforms concerned are those of Paris-CDG and Paris-Orly.
Sample 1
Scope Covered by Indicator. The luggage carousels concerned are those made available for passengers on arrival. - The platforms concerned are those of Paris-CDG and Paris-Orly.
Sample 1
Scope Covered by Indicator. The various types of public information systems taken into account are the following: - remote display televisions, - remote display screens, - remote display electronic signs; - The platforms concerned are those of Paris-CDG and Paris-Orly.
Sample 1
Scope Covered by Indicator. Screens, televisions and display boards in terminals. - The platforms concerned are those of Paris-CDG and Paris-Orly.
Sample 1
Scope Covered by Indicator. All the luggage trolley fleet. - The platforms concerned are those of Paris-CDG and Paris-Orly.
Sample 1
AutoNDA by SimpleDocs
Scope Covered by Indicator. All mail (written or electronic) containing complaints from the general public and sent to Aéroports de Paris, relating to the passage of passengers and the public, regardless of the party that is the subject of the complaint; - The platforms concerned are those of Paris-CDG and Paris-Orly.
Sample 1
Scope Covered by Indicator the contact parking stands scheduled to be put into service at the CDG1, CDG 2E and S3 terminals of the Xxxxx-Xxxxxxx-de-Gaulle airport.
Sample 1

Related to Scope Covered by Indicator

  • Supplier Diversity Seller shall comply with Xxxxx’s Supplier Diversity Program in accordance with Appendix V.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • RE-WEIGHING PRODUCT Deliveries are subject to re- weighing at the point of destination by the Authorized User. If shrinkage occurs which exceeds that normally allowable in the trade, the Authorized User shall have the option to require delivery of the difference in quantity or to reduce the payment accordingly. Such option shall be exercised in writing by the Authorized User.

  • Study Population ‌ Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 201 to be assigned to the study: n = 106 to be analysed: n = 106 Duration of intervention per patient of the intervention group: 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months post enterostomy closure, following enterostomy closure (12-month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 month of overall study duration).

  • Trials The Ship shall run the following test and trials:

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Influenza Vaccination The parties agree that influenza vaccinations may be beneficial for patients and employees. Upon a recommendation pertaining to a facility or a specifically designated area(s) thereof from the Medical Officer of Health or in compliance with applicable provincial legislation, the following rules will apply:

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Random Drug Testing All employees covered by this Agreement shall be subject to random drug testing in accordance with Appendix D.

  • Standard Samples Bid Specifications may indicate that the Product to be purchased must be equal to a standard sample on display in a place designated by the Commissioner and such sample will be made available to the Bidder for examination prior to the opening date. Failure by the Bidder to examine such sample shall not entitle the Bidder to any relief from the conditions imposed by the Bid Specifications.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!